Drug Trial Radar · NCT05407324
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
279
Planned (sponsor's estimate)
Start
Nov 15, 2022
Primary completion
Oct 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
Dazucorilant 300 mgDrug
300 mg of dazucorilant will be administered once daily in 4 capsules of 75 mg dazucorilant/capsule.
Dazucorilant 150 mgDrug
Dazucorilant and placebo will be administered once daily in 4 capsules, 2 capsules with 75 mg dazucorilant/capsule, and 2 capsules of placebo equivalent.
PlaceboOther
Placebo will be administered once daily in capsules of placebo equivalent.
DazucorilantDrug
Dazucorilant will be administered once daily in 75-mg capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.Time frame: Baseline to Week 24
- Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEsTime frame: Baseline to Week 24
- Incidence of treatment-emergent AEs and SAEsTime frame: Baseline up to Week 12
- Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drugTime frame: Baseline up to Week 12
Locations
35 sites in 10 countries. Site status is shown where the registry gives one.
062
Phoenix, Arizona
278
San Francisco, California
287
Neptune City, New Jersey
353
New York, New York
108
Leuven, Belgium
425
Hamilton, Ontario, Canada
273
Montreal, Quebec, Canada
422
Bron, France
258
Lille, France
257
Limoges, France
261
Marseille, France
423
Montpellier, France
259
Nice, France
262
Paris, France
256
Tours, France
255
Berlin, Germany
270
Bonn, Germany
268
Dresden, Germany
260
Hanover, Germany
265
Jena, Germany
386
München, Germany
267
Rostock, Germany
269
Ulm, Germany
253
Dublin, Ireland
264
Utrecht, Netherlands
283
Bydgoszcz, Poland
385
Krakow, Poland
254
Warsaw, Poland
274
Warsaw, Poland
302
Barcelona, Spain
115
Barcelona, Spain
303
Madrid, Spain
282
Málaga, Spain
194
Valencia, Spain
263
Stoke-on-Trent, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.